A Single Trial Result Doubled a $60 Billion Company Overnight — The Case Against Owning One Biotech

Doubling in a day is not normal. It is also not luck, exactly — it is the arithmetic of binary outcomes, and it is the single best teaching example in markets for why most investors should own biotech as a basket rather than as a bet.

Moderna announced that its personalised mRNA cancer vaccine, tested alongside Merck's Keytruda in more than 1,100 high-risk melanoma patients, met both its primary endpoint of reducing recurrence and its secondary endpoint of preventing spread. The stock roughly doubled. Merck, the much larger partner, rose about 8%.

Why the two moves were so different

That asymmetry is the whole lesson.

Merck is a diversified pharmaceutical company with many approved products and revenue streams. A successful trial adds a meaningful new indication for an existing blockbuster. Good news, modest move.

Moderna's valuation was substantially a function of whether its mRNA platform could be extended beyond vaccines into oncology. That is a question with essentially two answers. When the answer arrived, the stock did not adjust — it repriced from one scenario to another.

This is what "binary event" means in practice. Clinical-stage biotech does not trade on quarterly earnings. It trades on the probability-weighted value of a small number of yes/no outcomes, and those probabilities move in enormous jumps when data arrives.

The uncomfortable symmetry

Every article celebrating a 105% day should include the sentence nobody wants to read: the same mechanism runs in reverse.

Phase 3 failures routinely take biotech stocks down 60%, 70%, 80% in a single session. The distribution of outcomes is not a bell curve around a modest expected return. It is bimodal: a large gain or a devastating loss, with relatively little in between.

That is why an investor who buys one clinical-stage biotech and sizes it like a normal position has, whether they realise it or not, taken a leveraged bet on a scientific result they are almost certainly not qualified to evaluate.

What to do instead

Own the sector, not the stock. Biotech index funds hold dozens to hundreds of companies. Any single failure is absorbed; any single success contributes. You give up the chance of doubling in a day, and you eliminate the chance of losing 75% in one. For most people that is an excellent trade.

Two structural notes worth knowing: broad biotech indexes and large-cap biotech indexes behave quite differently, because the large-cap versions are dominated by a handful of profitable companies while the broader versions hold far more clinical-stage names — which makes them substantially more volatile.

If you must own individual names, size for total loss. The only defensible way to hold a clinical-stage biotech is at a position size where a complete wipeout is annoying rather than damaging. For most portfolios that means low single-digit percentages, and it means never adding to a loser hoping the next readout goes the other way.

Do not chase after the move. The 105% has happened. Buying now is a bet on the next set of questions — commercialisation, manufacturing, regulatory approval, pricing, competition — not on the result that already printed. Those are real risks that the doubled price now reflects some optimism about.

Understand what you actually own inside your index funds. Health care is one of the largest sectors in the S&P 500 and in most broad global funds. You already have exposure to the Mercks of the world. What you generally do not have, and probably do not need, is concentrated exposure to pre-revenue clinical companies.

The wider market signal

There is a second story here worth noting. On a day when chip stocks were falling globally and bond yields were the dominant narrative, health care and cyclicals led the S&P 500 higher.

That is rotation — money moving from expensive, long-duration technology into sectors with nearer-term cash flows, in an environment where the discount rate is rising. It is the same rotation showing up in Canadian gold miners outperforming Canadian banks, and in the Dow outperforming the Nasdaq.

For long-term index investors, rotation is not something to act on. It is something to recognise, so you understand why your portfolio is behaving the way it is.

Frequently asked questions